Overview

A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

Status:
Terminated
Trial end date:
2021-05-25
Target enrollment:
Participant gender:
Summary
The purpose of this study in participants with advanced cancer is to learn more about the safety of ramucirumab when given by injection under the skin (subcutaneous injection). The study will also measure how much ramucirumab gets into the bloodstream and how long it takes the body to get rid of it.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Ramucirumab